ERBB2 and breast carcinoma: For example, Janiszewska and colleagues employed FISH to assess the spatial heterogeneity of cellular genetic diversity and the changes in the frequency and topology of the PIK3CA mutation and Her‐2 amplification within Her‐2‐positive breast cancer during neoadjuvant therapy 27.